

### Biliary Tract Cancers

<b>ECOG-ACRIN EA2187</b> <b>NCT04175912</b>	<b>Temp closed</b> <b>to accrual</b> <b>3/31/21</b>	A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
--	---	--

### BioBanking

---

### Brain

<b>NRG BN007</b> <b>NCT04396860</b>	<b>Temp Closed</b> <b>to Accrual</b> <b>4/27/22</b>	A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab vs. Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
<b>NRG-BN011</b> <b>NCT05095379</b>		A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

### Breast - Neoadjuvant

### Breast - DCIS

<b>AFT-25 COMET</b> <b>NCT02926911</b>		Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
---	--	---

### Breast - Adjuvant Triple Negative

### BREAST - Adjuvant HR Positive

## BREAST - Adjuvant HER2+

<b>ECOG-ACRIN EA1181 NCT04266249</b>		(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
<b>Alliance A011801 NCT04457596</b>		The CompassHER2 Trials (COMprehensive use of Pathologic Repsonse ASSEssment to optimize Therapy in HER2-positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
<b>DFCI 21-159 ATEMPT NCT04893109</b>		A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab vs. Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT 2.0)

## Breast - Adjuvant XRT

<b>CCTG MA.39 NCT03488693</b>		A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
<b>SWOG S1706 NCT03598257</b>		A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy alone for Inflammatory Breast Cancer

## Breast - Metastatic

### Breast - Locally Advanced/Metastatic

#### HER2+/HR+

<b>DFCI 20-347 ADEPT NCT04569747</b>		A Single Arm Phase II Study of Adjuvant Endocrine Therapy, Subcutaneous Pertuzumab, and Trastuzumab Fixed-Dose Combination for Patients With Anatomic Stage I Hormone Receptor-Positive, HER2-Positive Breast Cancer
--	--	--

#### ER+/HER2-

### Triple Negative

<b>DFCI 18-617 NCT# N/A</b>		A Prospective Registry to Cure Triple-Negative Breast Cancer in Patients With Early-Stage or Newly Diagnosed Metastatic Disease: The TNBC Registry
---------------------------------	--	--

### Longitudinal Study

<b>DFCI 18-634 ELEVATE NCT03818087</b>		ELEVATE: Improving Outcomes for Older Patients with Breast Cancer: A Longitudinal Cohort and Patient Engagement Study
--	--	---

## Radiation

<b>NRG-BR007</b> <b>NCT04852887</b>		A Phase III Clinical Trial Evaluating DE-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score $\leq$ 18 Breast Cancer
--	--	--

## Children's Oncology Group Registry

<b>APEC14B1 (Patient's 25 and Younger)</b>		Project EveryChild: A Registry, Eligibility Screening, Biology and Outcome Registry
--	--	---

## Colorectal

<b>Alliance A021502</b> <b>NCT02912559</b>	<b>DTL Required</b>	Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
<b>Alliance A021703</b> <b>NCT04094688</b>		Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
<b>NRG GI004</b> <b>NCT02997228</b>	<b>DTL Required</b>	NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
<b>NRG-GI005</b> <b>NCT04068103</b>		Phase II/III Study of Circulating tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
<b>SWOG S1922</b> <b>NCT04205968</b>		Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

## Gastroesophageal

<b>EA2174</b> <b>NCT03604991</b>		A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
-------------------------------------	--	---

## Genitourinary

<b>ECOG EA8185</b> <b>NCT04216290</b>		Phase II Study of Bladder-Sparing Chemoradiation With MEDI4736 (durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE)
--	--	---

## Germ Cell

<b>AGCT1531</b> <b>NCT03067181</b> (Patients <50 years of age)		A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
<b>AGCT1532</b> <b>NCT02585697</b> (Patients <= 45 years of age)		A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

## GYN

<b>NRG GY014</b> <b>NCT03348631</b>		A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
<b>NRG GY019</b> <b>NCT04095364</b>		A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin /Maintenance Letrozole vs Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
<b>NRG GY012</b> <b>NCT03660826</b>		A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasterib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer
<b>NRG-GY018</b> <b>NCT03914612</b>		A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
<b>NRG-GY023</b> <b>NCT04739800</b>		A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

## Head and Neck

<b>NRG-HN009</b> <b>NCT05050162</b>		Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100mg/m <sup>2</sup> ) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40mg/m <sup>2</sup> ) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
--	--	---

## Hodgkin Lymphoma

<b>S1826</b> <b>NCT03907488</b>		A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vendotin(Adcetris) Plus AVD in Patients (Age >= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
------------------------------------	--	--

## Leukemia - Untreated/Newly Diagnosed

<b>Alliance A041701</b> <b>NCT03701308</b>	<b>DTL Required</b> <b>Temp. closed</b> <b>to accrual</b> <b>11/19/21</b>	A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
<b>Alliance A041702</b> <b>NCT03737981</b>		A Randomized Phase III Trial of Ibrutinib Plus Obintuzumab versus Ibrutinib Plus Venetoclax and Obintuzumab in Untreated Older Patients ( $\geq 65$ ) Years of Age) with Chronic Lymphocytic Leukemia (CLL)
<b>DFCI 18-089</b> <b>NCT03534323</b>		A Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Patients or Patients with Richter's Syndrome
<b>DFCI 18-226</b> <b>NCT03580928</b>		A Phase 2 Study of Acalabrutinib, Venetoclax, and Obintuzumab (AVO) for Initial Therapy of Chronic Lymphocytic Leukemia

## Lung Cancer - Screening Adjuvant

<b>Alliance A151216</b> <b>(ALCHEMIST)</b> <b>NCT02194738</b>		Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
---	--	--

## Lung Cancer - Adjuvant

<b>Alliance A081801</b> <b>NCT04267848</b>		Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
<b>ECOG E4512</b> <b>(ALCHEMIST)</b> <b>NCT 02201992</b>		A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
<b>SWOG 1827</b> <b>NCT04155034</b>		MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

## Lung Cancer - Genotyping

DFCI 19-523 NCT04166487		Pilot Study of Serial Plasma Genotyping to Guide the Adaptive Treatment of Advanced NSCLC Receiving First-Line Pembrolizumab
----------------------------	--	--

## Lung Cancer - Unresectable

ECOG-ACRIN EA5181 NCT04092283		Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
----------------------------------	--	---

## Lung Cancer - 1st Line Metastatic

ECOG-ACRIN EA5163 NCT03793179		INSIGNIA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Non-squamous, Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis
----------------------------------	--	--

## Lung Cancer - 2nd Line Metastatic

LUNGMAP NCT02154490		A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
SWOG 1900E NCT04625647		Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
SWOG S1800D NCT05096663		A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)

## Lymphoma

Alliance A051701 NCT03984448	Temp closed to accrual 8/2/2021	Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MC/BCL2 Double-Hit and Double-Expressing Lymphomas
ECOG-ACRIN EA4181 NCT04115631		A Randomized 3 Arm Phase II Study Comparing 1) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR), 2) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients $\leq$ 70 Years old with Untreated Mantle Cell Lymphoma
ANHL1931 NCT04759586		A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma (Patients $\geq$ 2 years of age)

## MCGI

<b>MCGI 2.0</b>		The Maine Cancer Genomics Initiative (MCGI) 2.0: A Study of Oncology Clinician and Patient Experiences with Clinical Genomics in Northern New England
-----------------	--	---

## Melanoma - Locally Advanced Metastatic

<b>ECOG-ACRIN EA6141 NCT02339571</b>		Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
--	--	--

## Melanoma - Adjuvant

### Merkel Cell

<b>EA6174 NCT03712605</b>		STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, A Phase III Trial
-------------------------------	--	--

## Multiple Tumor Types

<b>ECOG-ACRIN EAY131 (MATCH) NCT02465060</b>		Molecular Analysis for Therapy Choice (MATCH)
--	--	---

## Myeloma

<b>SWOG S1803 NCT04071457</b>		Phase III Study of Daratumumab/HuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as PostAutologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY)
<b>AFT-41 NCT04009109</b>		A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma

## Myeloma - Relapsed/Refractory

### Prevention

<b>Alliance A151804 NCT04242095</b>		Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
<b>Alliance A221805 NCT04137107</b>		Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

## Prostate

SWOG S1802 NCT03678025		Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
NRG-GU008 NCT04134260		Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy

## Rare Tumors

SWOG S1609 NCT02834013		DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
TAPUR NCT02693535		The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

## Renal

Alliance A031704 (PDIGREE) NCT03793166		PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGFTKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
--	--	--

## Rhabdomyosarcoma

ARST1431 NCT02567435 (Patients $\leq$ 40 years of age)	Temp closed to accrual 1/6/22	A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
---	-------------------------------------	--